Roche and High Throughput Genomics Partner for Advanced Gene Expression Analysis Solution

(PresseBox) ( Madison, WI, USA, )
Roche NimbleGen (SIX: RO, ROG; OTCQX: RHHBY) and High Throughput Genomics, Inc. (HTG), provider of the quantitative Nuclease Protection Assay (qNPA), have entered into a supply agreement. Under the agreement, Roche NimbleGen will provide HTG with high density, multiplex DNA microarray slides for advanced gene expression analysis.

HTG will apply the company’s quantitative nuclease protection assay (qNPA) process to the microarrays to enable researchers to quickly and efficiently measure the gene expression levels in a variety of sample types. The agreement enhances HTG’s existing service capability offering with the ability to take a broader look at gene expression through the multiplex capability of the Roche NimbleGen microarrays. Sample preparation using qNPA technology allows for a much simpler, more cost-effective workflow versus traditional labeling methods, while the Roche NimbleGen multiplex technology offers a cost-effective high density microarray providing in depth gene expression information.

“HTG’s agreement with Roche NimbleGen affords us the opportunity to provide our customers with customizable content and an attractive sample preparation and processing format. Compared with other vendors, Roche NimbleGen was able to offer us unique and differentiated array synthesis and formatting capabilities that best meet our client needs,” said T.J. Johnson, president and CEO, HTG. “The combination of low cost, flexibility, and high throughput means HTG’s customers can derive substantial benefits quickly and we can increase the plex in the analysis process as needed.”

Gerd Maass, CEO of Roche NimbleGen said, “The partnership with HTG showcases the strengths of the two companies and the flexibility of the NimbleGen Arrays by pairing two innovative
technologies to provide flexibility, time savings, and cost savings while offering the significant in depth genetic information that our high density arrays provide.”

For more information on Roche NimbleGen microarrays, go to www.nimblegen.com.

About HTG

Privately-held HTG is based in Tucson, Arizona. Investors in the company include Solstice Capital, Valley Ventures, Merck Capital Ventures, Village Ventures and Arcturus Capital. Additional information is available at www.htgenomics.com.

HTG's qNPA technology is used to carry out quantitative, multiplexed gene-based drug discovery programs, including target evaluation; HTS lead optimization, metabolism and toxicology. HTG's platform is highly flexible and designed automation-friendly; it allows scientists to test any sample, including fixed tissues, without RNA extraction or target amplification. The technology is ideal for detecting small, yet important changes in gene expression levels which other gene expression platforms cannot reliably detect.

All trademarks used or mentioned in this release are protected by law.

NIMBLEGEN is a trademark of Roche.
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to service@pressebox.de.